ClinicalTrials.gg
TerminatedNCT06514742VENTURA-7Updated Feb 17, 2026

A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant

A Phase 3 interventional study of Aticaprant and Placebo in Depressive Disorder, Major and Anhedonia, sponsored by Janssen Research & Development, LLC. Terminated at 84 sites in 9 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Why this study was terminated
Early study termination due to insufficient efficacy.

From the registry’s dates

  • Primary completion was Apr 2025, 1 year 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
101
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies in Depressive Disorder, Major by Johnson & Johnson — 5 open to participants now, 5 under way, 5 of them phase 3. Depressive Disorder, Major · Johnson & Johnson.

Enrollment
37th of 52
101 · median 203
Started
2024
with 4 others
Phase 3
23 of 59
5 open now
Registered
52nd of 59
by date

Among the 59 studies in Depressive Disorder, Major by Johnson & Johnson, this one is the 37th largest by enrollment of the 52 interventional ones that give a count, is one of 5 that started in 2024, is one of 23 in phase 3, and was the 52nd registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

5 of the 59 studies in Depressive Disorder, Major by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Depressive Disorder, Major by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate how well aticaprant works as compared with placebo when given along with an antidepressant therapy in improving the depressive symptoms in adult participants with major depressive disorder (MDD) with moderate to severe anhedonia (ANH+) who have not responded well to current antidepressant therapy with a selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor (SSRI or SNRI).

03

Conditions studied

  • Depressive Disorder, Major
  • Anhedonia
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be medically stable based on physical examination (including a brief neurologic examination), medical history, vital signs (including blood pressure), and 12-lead (ECG) performed at screening and double blind (DB) baseline
  • Meet -5th edition (DSM-5) diagnostic criteria for recurrent or single episode major depressive disorder (MDD), without psychotic features (DSM-5 296.22, 296.23, 296.32, or 296.33), based upon clinical assessment and confirmed by the structured clinical interview for DSM-5 axis I disorders-clinical trials version (SCID-CT)
  • Have symptoms of anhedonia based on clinical assessment and confirmed by presence of anhedonia (positive response to MDE module symptom Item 2) on the SCID-CT at screening
  • Have had an inadequate response to at least 1 and up to 5 (inclusive) oral antidepressant treatments, administered at an adequate dose
  • Is currently receiving and tolerating well any one of the following selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor (SSRI or SNRI) antidepressants at screening, in any approved formulation and available in the participating country/territory: citalopram, duloxetine, escitalopram, fluvoxamine, fluoxetine, milnacipran, levomilnacipran, paroxetine, sertraline, venlafaxine, or desvenlafaxine at a stable dose (at or above the minimum therapeutic dose per Massachusetts general hospital antidepressant treatment response questionnaire (MGH ATRQ) for at least 6 weeks. The current antidepressant cannot be the first antidepressant treatment for the first lifetime episode of depression

Exclusion criteria

Exclusion Criteria:

  • Has had no response (treatment failure) to 2 or more consecutive antidepressant treatments administered at an adequate dose (at or above the minimum therapeutic dose) and duration (at least 6 weeks) in the current episode of depression including the current SSRI/SNRI (that is the one to be continued in the treatment phases) assessed using the MGH ATRQ
  • Has one or more of the following diagnoses: (1) a current or prior (lifetime) diagnosis of: (a) a psychotic disorder or MDD with psychotic features, (b) bipolar or related disorders, (c) intellectual disability, (d) autism spectrum disorder, (e) borderline personality disorder, (f) antisocial personality disorder, (g) histrionic personality disorder, (h) narcissistic personality disorders, (i) somatoform disorders; (2) A primary DSM-5 diagnosis (which has been the primary focus of psychiatric treatment within the past 2 years) of: (a) panic disorder, (b) generalized anxiety disorder, (c) social anxiety disorder, (d) specific phobia; (3) A current (in the past year) DSM-5 diagnosis of: (a) obsessive-compulsive disorder, (b) post-traumatic stress disorder, (c) anorexia nervosa, (d) bulimia nervosa
  • Has a history or evidence of noncompliance with current antidepressant therapy
  • Has a history of moderate-to-severe substance use disorder including alcohol use disorder according to DSM-5 criteria within 6 months before screening
  • Has in the current depressive episode had vagal nerve stimulation or deep brain stimulation device in the current episode or has had an inadequate response to an adequate course of intravenous or intranasal ketamine or esketamine (greater than [>] 2 treatments), or electroconvulsive therapy (that is at least 7 treatments)
  • Has homicidal ideation/intent, per the investigator's clinical judgment, or has suicidal ideation with some intent to act within 3 months prior to the start of the screening phase, per the investigator's clinical judgment or based on the columbia suicidality severity rating scale (C-SSRS), corresponding to a response of "Yes" on Item 4 (active suicidal ideation with some intent to act, without specific plan) or Item 5 (active suicidal ideation with specific plan and intent) for suicidal ideation on the C-SSRS, or a history of suicidal behavior within the past 6 months prior to the start of the screening phase. Participants reporting suicidal ideation with intent to act or suicidal behavior at DB baseline should be excluded
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
101 participants (actual)

Study arms

  • Experimental
    Aticaprant

    Drug: Aticaprant

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • Aticaprant tablet will be administered orally.

    Also known as: JNJ-67953964

  • OtherPlacebo

    Placebo tablet will be administered orally.

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Day 43 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

    Change from baseline to Day 43 in MADRS total score will be reported.

    Time frame: Baseline to Day 43

Secondary outcomes

  1. Change From Baseline to Day 43 in Dimensional Anhedonia Rating Scale (DARS) Total Score

    Change from baseline to Day 43 in DARS total score will be reported.

    Time frame: Baseline to Day 43

  2. Change From Baseline to Day 43 in Changes in Sexual Function Questionnaire - 14 items (CSFQ-14) Total Score

    Change from baseline to Day 43 in CSFQ-14 total score will be reported.

    Time frame: Baseline to Day 43

  3. Change From Baseline Over Time in MADRS Total Score

    Change from baseline over time in the MADRS total score will be reported.

    Time frame: For double-blind (DB) treatment phase: Baseline (Day 1), Up to Day 43; For open-label (OL) treatment phase: Baseline (Day 43), Up to Week 31

  4. Percentage of responders on Depressive Symptoms Scale, Defined as a Greater Than or Equal to (>=) 50 Percent (%) Improvement in MADRS Total Score From Baseline to Day 43

    Percentage of responders on depressive symptoms scale, defined as a \>= 50 % improvement in MADRS total score from baseline to Day 43 will be reported.

    Time frame: Baseline to Day 43

  5. Percentage of Participants With Remission of Depressive Symptoms, Defined as a MADRS Total Score Less Than or Equal to (<=)10 at Day 43

    Percentage of participants with remission of depressive symptoms, defined as a MADRS total score \<=10 at Day 43 will be reported.

    Time frame: Day 43

  6. Change From Baseline to Day 43 in Patient Health Questionnaire, 9-item (PHQ-9) Total Score

    Change from baseline to Day 43 in the PHQ-9 total score will be reported.

    Time frame: Baseline to Day 43

  7. Change From Baseline Over Time in DARS Total score.

    Change from baseline over time in DARS total score will be reported.

    Time frame: For DB treatment phase: Baseline (Day 1), Up to Day 43; For OL treatment phase: Baseline (Day 43), Up to Week 31

  8. Change From Baseline Over Time in the PHQ-9 Anhedonia-Specific Item (PHQ-9, item 1).

    Change from baseline over time in the PHQ-9 Anhedonia-specific item (PHQ-9, Item 1) will be reported.

    Time frame: For DB treatment phase: Baseline (Day 1), Up to Day 43; For OL treatment phase: Baseline (Day 43), Up to Week 31

  9. Percentage of Participants With a Score Less than (<) 2 in the PHQ-9 Anhedonia-specific Item (PHQ-9, Item 1) at Day 43

    Percentage of participants with a score \< 2 in the PHQ-9 Anhedonia-specific Item (PHQ-9, Item 1) at Day 43 will be reported.

    Time frame: Day 43

07

Study locations

84 sites
  • UAB Huntsville Regional Medical Campus
    Huntsville, Alabama 35801, United States
  • IMA Clinical Research PC
    Phoenix, Arizona 85012, United States
  • Noble Clinical Research
    Tucson, Arizona 85704, United States
  • Advanced Research Center Inc
    Anaheim, California 92805, United States
  • CI Trials
    Bellflower, California 90706, United States
  • Behavioral Research Specialists LLC
    Glendale, California 91206, United States
  • Sun Valley Research Center
    Imperial, California 92251, United States
  • ATP Clinical Research
    Orange, California 92866, United States
  • Lumos Clinical Research Center LLC
    San Jose, California 95124, United States
  • Viking Clinical Research Ltd
    Temecula, California 92591, United States
  • Sunwise Clinical Research
    Walnut Creek, California 94596, United States
  • MCB Clinical Research Centers LLC
    Colorado Springs, Colorado 80910, United States
  • Humanity Clinical Research Corp
    Aventura, Florida 33180, United States
  • Elligo Independent Research Sites Mindful Behavioral Health
    Boca Raton, Florida 33431, United States
  • Gulfcoast Medical Research Center
    Fort Myers, Florida 33912, United States
  • New Life Medical Research Center, Inc.
    Hialeah, Florida 33012, United States
  • LCC Medical Research Institute Inc
    Miami, Florida 33126, United States
  • Floridian Clinical Research LLC
    Miami, Florida 33135, United States
  • Medquest Translational Sciences
    Miami Lakes, Florida 33016, United States
  • Best Choice Medical and Research Service
    Pembroke Pines, Florida 33024, United States
  • K2 Medical Research
    Tampa, Florida 33607, United States
  • Neuroscience Research Institute
    West Palm Beach, Florida 33407, United States
  • Accelerated Clinical Trials LLC
    Peachtree Corners, Georgia 30071, United States
  • Southern Illinois University School of Medicine
    Springfield, Illinois 62702, United States
  • DelRicht Research
    New Orleans, Louisiana 70115, United States
  • CBH Health
    Gaithersburg, Maryland 20877, United States
  • Integrative Clinical Trials LLC
    Brooklyn, New York 11229, United States
  • Fieve Clinical Research Inc
    New York, New York 10017, United States
  • New Hope Clinical Research
    Charlotte, North Carolina 28211, United States
  • Patient Priority Clinical Sites LLC
    Cincinnati, Ohio 45215, United States
  • OSU Department of Psychiatry and Behavioral Health
    Columbus, Ohio 43210, United States
  • Conrad Clinical Research
    Edmond, Oklahoma 73013, United States
  • Suburban Research Associates
    Media, Pennsylvania 19063, United States
  • UTHealth Houston Center for Interventional Psychiatry
    Houston, Texas 77030, United States
  • Brain Health Consultants
    Houston, Texas 77046, United States
  • Red Oak Psychiatry Associates
    Houston, Texas 77090, United States
  • Revival Research Institute LLC
    McKinney, Texas 75071, United States
  • Perceptive Pharma Research
    Richmond, Texas 77407, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
  • Anima
    Alken, 3570, Belgium
  • Chu Tivoli
    La Louvière, 7100, Belgium
  • Centre Hospitalier Specialise Notre Dame Des Anges Asbl
    Liège, 4000, Belgium
  • Meclinas
    Mechelen, 2800, Belgium
  • Universidade Federal do Ceara Hospital Universitario Walter Cantidio
    Fortaleza, 60175 270, Brazil
  • NPCRS Nucleo de Pesquisa Clinica do Rio Grande do Sul
    Porto Alegre, 90430001, Brazil
  • Centro Integrado Facili
    São Bernardo do Campo, 09726 150, Brazil
  • BR Trials
    São Paulo, 01236030, Brazil
  • Mental Health Center Prof. Dr. Ivan Temkov
    Burgas, 8001, Bulgaria
  • Medical Center Mentalcare OOD
    Plovdiv, 4004, Bulgaria
  • MHC - Sofia, EOOD
    Sofia, 1202, Bulgaria
  • Centre for Mental Health Prof.N.Shipkovenski EOOD
    Sofia, 1377, Bulgaria
  • Terveystalo Ruoholahti
    Helsinki, 00180, Finland
  • Savon Psykiatripalvelu
    Kuopio, 70110, Finland
  • Northern Clinical Trial Coordinators
    Oulu, 90100, Finland
  • Oulu Mentalcare Oy
    Oulu, 90100, Finland
  • Mehilainen Finlayson
    Tampere, 33210, Finland
  • Clinical Research Services Turku - CRST
    Turku, 20520, Finland
  • Semmelweis Egyetem
    Budapest, 1083, Hungary
  • Eszak Budai Szent Janos Centrumkorhaz
    Budapest, 1125, Hungary
  • Processus Kft
    Budapest, 1137, Hungary
  • Bugat Pal Korhaz
    Gyöngyös, 3200, Hungary
  • Gyor Moson Sopron Varmegyei Petz Aladar Egyetemi Oktato Korhaz
    Győr, 9024, Hungary
  • Dr Mathe es Tarsa Bt
    Kalocsa, 6300, Hungary
  • Pte Aok Pszichiatriai Klinika
    Pécs, 7623, Hungary
  • PsychoTech Kft
    Pécs, 7633, Hungary
  • Tolna Varmegyei Balassa Janos Korhaz
    Szekszárd, 7100, Hungary
  • Osrodek Badan Klinicznych CLINSANTE S C Ewa Galczak Nowak Malgorzata Trzaska
    Bydgoszcz, 85 794, Poland
  • Centrum Zdrowia Alcea
    Gdansk, 80 283, Poland
  • Centrum Badan Klinicznych PI House sp z o o
    Gdansk, 80 546, Poland
  • Osrodek Badan Klinicznych CLINSANTE S C
    Torun, 87 100, Poland
  • Ginemedica Sp. z o.o.
    Wroclaw, 50-414, Poland
  • Hosp. de La Santa Creu I Sant Pau
    Barcelona, 08025, Spain
  • Institucion Hosp Hestia Palau
    Barcelona, 08025, Spain
  • Hospital Ramon y Cajal
    Madrid, 28034, Spain
  • Centro Salud Mental La Corredoria
    Oviedo, 33011, Spain
  • Corporacio Sanitari Parc Tauli
    Sabadell, 08208, Spain
  • Hosp. Virgen Del Rocio
    Seville, 41013, Spain
  • Hosp. Alvaro Cunqueiro
    Vigo, 36312, Spain
  • Hosp. Prov. de Zamora
    Zamora, 49021, Spain
  • Affecta Pskyiatrimottagning
    Halmstad, SE-30248, Sweden
  • Linkoping University Hospital
    Linköping, 58185, Sweden
  • ProbarE i Lund AB
    Lund, 22222, Sweden
  • ProbarE i Stockholm AB
    Stockholm, 113 29, Sweden
  • Studieenheten Akademiskt Specialistcentrum Stockholm
    Stockholm, 113 61, Sweden
08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2024 to primary completion in Apr 2025, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2024
First posted
Jul 23, 2024
StartActual
Jun 26, 2024
Primary completionActual
Apr 8, 2025
CompletionActual
Apr 24, 2025
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06514742
Responsible party
Sponsor
First posted
Jul 23, 2024
Start date
Jun 26, 2024
Primary completion
Apr 8, 2025
Completion
Apr 24, 2025
Last update
Feb 17, 2026

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aticaprant

Start the discussion